Arcturus Therapeutics Holdings Inc. - 8-K Filing
Arcturus Therapeutics appointed Dennis Mulroy as Chief Financial Officer effective May 1, 2026. Mulroy's compensation includes a $520,000 annual base salary, a 40% discretionary bonus, and options to acquire 100,000 shares with a four-year vesting schedule. The company also announced financial results for the quarter ended March 31, 2026, and provided a corporate update in a May 7, 2026 press release. (Items: 2.02 of this Current Report on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $ARCT